Some molecular subtypes, most notably mutant EGFR NSCLC but ALK rearrangement tumors as well [4–6], respond poorly to anti-PD-L1 antibody therapy although the reason(s) for the resistance have not been described. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.